Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Bought by GAMMA Investing LLC

GAMMA Investing LLC lifted its stake in Astria Therapeutics, Inc. (NASDAQ:ATXS) by 1,127.4% in the first quarter, HoldingsChannel reports. The fund owned 8,678 shares of the biotechnology company’s stock after purchasing an additional 7,971 shares during the quarter. GAMMA Investing LLC’s holdings in Astria Therapeutics were worth $46,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Rhumbline Advisers lifted its stake in Astria Therapeutics by 2.3% during the fourth quarter. Rhumbline Advisers now owns 62,163 shares of the biotechnology company’s stock valued at $556,000 after purchasing an additional 1,381 shares during the last quarter. New York State Common Retirement Fund lifted its stake in Astria Therapeutics by 67.0% during the fourth quarter. New York State Common Retirement Fund now owns 10,720 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 4,300 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Astria Therapeutics by 2.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 322,576 shares of the biotechnology company’s stock valued at $2,884,000 after purchasing an additional 8,311 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in Astria Therapeutics during the fourth quarter valued at approximately $707,000. Finally, Swiss National Bank lifted its stake in Astria Therapeutics by 13.1% during the fourth quarter. Swiss National Bank now owns 66,600 shares of the biotechnology company’s stock valued at $595,000 after purchasing an additional 7,700 shares during the last quarter. 98.98% of the stock is owned by institutional investors and hedge funds.

Astria Therapeutics Stock Performance

NASDAQ ATXS opened at $5.44 on Friday. Astria Therapeutics, Inc. has a twelve month low of $3.56 and a twelve month high of $12.92. The stock has a market cap of $306.98 million, a price-to-earnings ratio of -2.91 and a beta of 0.39. The firm’s 50 day moving average price is $4.92 and its two-hundred day moving average price is $6.31.

Astria Therapeutics (NASDAQ:ATXS) last posted its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.10). On average, research analysts forecast that Astria Therapeutics, Inc. will post -1.65 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. HC Wainwright reissued a “buy” rating and set a $16.00 target price on shares of Astria Therapeutics in a research note on Friday, June 13th. Wedbush reissued an “outperform” rating and set a $28.00 target price (up from $27.00) on shares of Astria Therapeutics in a research note on Wednesday, March 12th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $47.00 target price on shares of Astria Therapeutics in a research note on Wednesday, May 14th. Six equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Astria Therapeutics currently has an average rating of “Buy” and a consensus price target of $30.00.

Astria Therapeutics Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.